$LENZ News
Last published 2w ago
- 2w agoLENZLENZ Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 2.05 Item 5.02 Item 9.01
- 2w agoLENZLENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO SuccessionGlobeNewswireQ3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to prioritize consumer
- 2w agoLENZLENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026GlobeNewswireSAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only
- 3mo agoLENZLENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026GlobeNewswireSAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only
- 4mo agoLENZLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of PresbyopiaGlobeNewswireVIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online
- 4mo agoLENZLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New ZealandGlobeNewswireSAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and
- 5mo agoLENZLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater ChinaGlobeNewswireSAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution)
- 5mo agoLENZLENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only
- 6mo agoLENZLENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireQ1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026
- 6mo agoLENZLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor ConferenceGlobeNewswireSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only
- 6mo agoLENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomGlobeNewswireMHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ
- 7mo agoLENZLENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireLaunched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid
- 8mo agoLENZLENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of PresbyopiaGlobeNewswireMAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ's strategy to expand global access to VIZZ Submission of MAA in Europe results in the fifth ex-U.S. regulatory submission for
- 8mo agoLENZLENZ Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only
- 10mo agoLENZLENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaignGlobeNewswireStruggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The "Make it VIZZable" campaign features SJP enjoying the everyday
- 10mo agoLENZLENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaignPR NewswireLENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), today announced the launch of "Make it VIZZable", the VIZZ consumer campaign with...
- 10mo agoLENZLENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate UpdatesGlobeNewswireLaunched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product
- 10mo agoLENZLENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle EastGlobeNewswireSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lunatus Marketing & Consulting FZCO ("Lunatus") today announced an exclusive distribution
- 11mo agoLENZLENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of PresbyopiaGlobeNewswireSAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New
- 11mo agoLENZLENZ Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and
- 1y agoLENZLENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireVIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs
- 1y agoLENZLENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025GlobeNewswireSAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and
- 1y agoLENZLENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United StatesPR NewswireLENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only...
- 1y agoLENZLENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United StatesGlobeNewswireVIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only
- 1y agoLENZLENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoLENZLENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoLENZLENZ Therapeutics to Present at Upcoming Investor and Medical ConferencesGlobeNewswireSAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and
- 1y agoLENZLENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of PresbyopiaGlobeNewswireVIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to
- 1y agoLENZLENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireNew Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities
- 1y agoLENZLENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of PresbyopiaGlobeNewswireSAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the
- 1y agoLENZLENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in CanadaGlobeNewswireSAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Laboratoires Théa ("Théa") announced an exclusive license and commercialization agreement for Théa to
- 1y agoLENZLENZ Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoLENZLENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast AsiaGlobeNewswireSAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive license and
- 1y agoLENZLENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireNew Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly
- 1y agoLENZLENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care ConferenceGlobeNewswireSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoLENZLENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025GlobeNewswireSAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoABOSCLYMLENZSLDB+1Climb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
- 1y agoLENZLENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireNew Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product
- 1y agoLENZLENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025GlobeNewswireSAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoLENZLENZ Therapeutics to Host Commercial Day on April 15, 2025GlobeNewswireSAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoLENZLENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 1y agoLENZLENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 2y agoLENZLENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLENZLENZ Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswireNew Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ
- 2y agoLENZLENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024GlobeNewswireSAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only
- 2y agoLENZCORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100GlobeNewswirePrimary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more
- 2y agoLENZLENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of PresbyopiaGlobeNewswireSAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye
- 2y agoABOSLENZLucy Therapeutics Appoints Kim Drapkin as Board ChairBusiness WireDrapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for
- 2y agoLENZLENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical ConferencesGlobeNewswireSAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near
- 2y agoLENZLENZ Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown